Expertise in
17
conditions

Dr. Ryan Lynch

Hematology
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 
Offers Telehealth
Expertise in
17
conditions
Rachel Loschiavo PA-C
825 Eastlake Ave E, 
Seattle, WA 

Overview

Ryan Lynch is a Hematologist practicing medicine in Seattle, Washington.

Dr. Lynch is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 73 peer reviewed articles and participating in 7 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in WA

Hospital Affiliations

University Of Washington Medical Ctr

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Group Health Cooperative
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
PacificSource
  • PPO
Premera
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Rachel Loschiavo Pa-C
825 Eastlake Ave E, Seattle, WA 98109

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Pilot Study of Subcutaneous Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for Untreated Indolent B-Cell Non-Hodgkin Lymphoma
A Pilot Study of Subcutaneous Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for Untreated Indolent B-Cell Non-Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Mosunetuzumab, Obinutuzumab, Polatuzumab Vedotin
Study Phase: Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine, and Dacarbazine (APVD) for Patients With Untreated Classical Hodgkin Lymphoma
A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine, and Dacarbazine (APVD) for Patients With Untreated Classical Hodgkin Lymphoma
Enrollment Status: Completed
Publish Date: August 05, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Dacarbazine, Doxorubicin, Pembrolizumab, Vinblastine
Study Phase: Phase 1/Phase 2
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drug: CYT-0851
Study Phase: Phase 1/Phase 2
A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular Lymphoma
A Phase I Study Evaluating Copanlisib in Combination With R-GCD (Gemcitabine, Carboplatin, Dexamethasone, and Rituximab) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and High-Risk Follicular Lymphoma
Enrollment Status: Terminated
Publish Date: June 29, 2023
Intervention Type: Drug, Biological
Study Drugs: Copanlisib, Gemcitabine, Carboplatin, Dexamethasone, Rituximab, Pegfilgrastim
Study Phase: Phase 1
A Phase II Trial of Umbralisib and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
A Phase II Trial of Umbralisib and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: May 03, 2023
Intervention Type: Biological, Drug
Study Drugs: Pembrolizumab, Umbralisib
Study Phase: Phase 2
MRD-Guided Abbreviation of Bendamustine and Rituximab Chemotherapy in Combination With Copanlisib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
MRD-Guided Abbreviation of Bendamustine and Rituximab Chemotherapy in Combination With Copanlisib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Terminated
Publish Date: April 11, 2022
Intervention Type: Drug, Biological
Study Drugs: Copanlisib, Rituximab, Bendamustine
Study Phase: Phase 2
View 6 Less Clinical Trials

73 Total Publications

Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.
Journal: American journal of hematology
Published: March 25, 2026
Similar Doctors
Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mazyar Shadman is a Hematologist practicing medicine in Seattle, Washington. Dr. Shadman is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Small Lymphocytic Lymphoma (SLL), Non-Hodgkin Lymphoma, and Bone Marrow Transplant.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
855-557-0555
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrei Shustov is a Hematologist practicing medicine in Seattle, Washington. Dr. Shustov is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

Rachel Loschiavo PA-C

825 Eastlake Ave E, 
Seattle, WA 
 (0.1 miles away)
206-606-1955
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chaitra Ujjani is a Hematologist practicing medicine in Seattle, Washington. Dr. Ujjani is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Chronic B-Cell Leukemia (CBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Ryan Lynch

How do I make an appointment with Dr. Ryan Lynch?

You can book an appointment with Dr. Ryan Lynch by calling their office at 206-288-7222. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ryan Lynch a top-rated expert for Hodgkin Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ryan Lynch is classified as an Elite expert for Hodgkin Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ryan Lynch specialize in?

While Dr. Ryan Lynch is a Hematology, they have specific expertise in Hodgkin Lymphoma, Classical Hodgkin Lymphoma, and Follicular Lymphoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Ryan Lynch participate in research or clinical trials?

Yes. Dr. Ryan Lynch has published 73 articles and abstracts on conditions like Hodgkin Lymphoma. You can view a list of Dr. Ryan Lynch's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ryan Lynch accept my insurance?

Dr. Ryan Lynch accepts most major insurance plans, including Aetna and Blue Shield of California. We recommend calling the office directly at 206-288-7222 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lynch's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 12 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile